At National Path Lab, we are committed to bringing the most advanced diagnostic technologies to Nepal. 

As part of this commitment, we are now offering the PGT-A test (Preimplantation Genetic Testing for Aneuploidy) in Nepal—an essential advancement in IVF (In Vitro Fertilization) care.

PGT-A is a genetic screening test performed during the IVF process, before embryo implantation. 

It allows us to assess whether an embryo has the correct number of chromosomes, helping clinicians make more informed decisions during embryo selection.

What is the PGT-A Test?

The PGT-A test is designed to detect chromosomal abnormalities (aneuploidy) in embryos. These abnormalities are a major cause of IVF failure, miscarriage, and certain genetic conditions.

Using Next-Generation Sequencing (NGS) technology, we analyze embryos at the blastocyst stage by examining a small number of cells. This enables precise evaluation of chromosomal balance before implantation.

What Conditions Does PGT-A Detect?

The PGT-A test helps identify risks associated with:

• Trisomy 21 (Down Syndrome)

• Trisomy 18 (Edwards Syndrome)

• Trisomy 13 (Patau Syndrome)

• Monosomies

• Other chromosomal imbalances

By identifying these risks early, PGT-A supports better clinical decision-making and improves the chances of a healthy pregnancy.

Who Should Consider PGT-A During IVF?

PGT-A is particularly useful for:

• Couples undergoing IVF or ICSI

• Women above 35 years of age

• Recurrent IVF failure

• Recurrent pregnancy loss (miscarriages)

• Known chromosomal abnormalities in either partner

• Severe male factor infertility

Why PGT-A Matters in IVF

In IVF, not all embryos have the correct chromosomal structure. Even healthy-looking embryos may carry genetic abnormalities that affect implantation or pregnancy outcomes.

The PGT-A test allows for:

• More informed embryo selection

• Reduced risk of miscarriage

• Improved IVF success rates

• Better planning of IVF cycles

Our Technology and Process

At National Path Lab, we use advanced NGS-based genetic analysis to ensure high accuracy in PGT-A testing.

The process involves:

1. Embryo biopsy at the blastocyst stage (performed at IVF centers)

2. Genetic analysis at our laboratory

3. Detailed reporting to support clinical decisions

The test requires an embryo biopsy sample collected at an IVF lab. Results are typically available within 10–12 days, enabling timely IVF cycle planning.

PGT-A Test Now Available in Nepal

With the introduction of the PGT-A test at National Path Lab, advanced IVF genetic screening is now available within Nepal. This reduces dependence on international laboratories and supports faster turnaround times for clinicians and fertility centers.

We believe that access to advanced genetic diagnostics like PGT-A will play a critical role in improving IVF outcomes and supporting safer, more informed pregnancies.

If you are a clinician, fertility specialist, or IVF center looking to integrate PGT-A into your practice, we invite you to collaborate with us.